---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-006317"
form_type: "8-K"
ticker: "INBS"
cik: "0001725430"
company_name: "INTELLIGENT BIO SOLUTIONS INC."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:04:44.818717+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Intelligent Bio Solutions Q2 revenue $896,774, up 48% YoY; reader sales surge 104%

## Summary
- Q2 total revenue $896,774, up 48% YoY; reader sales $246,519 (+104%), cartridge sales $516,754 (+33%).
- First-half FY2026 revenue $2.01M (+36% YoY); gross margin improved to 49% from 39%.
- Closed $10M private placement (net $9.4M received Jan 2, 2026) for working capital and FDA 510(k) submission.
- Initiated additional clinical studies for FDA 510(k); plans for U.S. market entry.
- Strategic alliance with Vlepis Pty Ltd for consumer health monitoring; major industrial service contract.

## SEC filing metadata
- accession: 0001493152-26-006317
- form_type: 8-K
- ticker: INBS
- cik: 0001725430
- company_name: INTELLIGENT BIO SOLUTIONS INC.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725430/000149315226006317/0001493152-26-006317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725430/000149315226006317/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-006317
- JSON: https://secwatch.observer/filing/0001493152-26-006317.json
- Plain text: https://secwatch.observer/filing/0001493152-26-006317.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.